Poly Medicure logo

Poly Medicure financials: balance sheet, profit and loss, cash flow

NSE: POLYMEDBSE: 531768Healthcare Equipment & SuppliesSmall Cap

Poly Medicure Limited · Face value ₹5 · Listed Jun 1996 on BSE, Dec 2011 on NSE
Last close ₹1,461.90down ₹14.10 (0.96%)BSE ₹1,462.90

Share price at the NSE close on 29 Oct 2026. Previous close ₹1,476.00.

29 Oct: open ₹1,480.00, high ₹1,480.20, low ₹1,446.10

52-week range of traded prices to 29 Oct 2026
₹1,182.00Low, 30 Mar 2026₹2,094.30High, 11 Nov 2025
Market cap
₹14,818 Cr425th largest listed
P/E
47.03
P/B
4.77
Dividend yield
0.24%
ROE
10.7%
ROCE
9.5%
Debt to equity
0.11
Volume, NSE
36,08750.2% delivered

Poly Medicure's financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Poly Medicure annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
45552Mar 1752271Mar 1861165137Mar 1968796168Mar 20786136102Mar 21923147125Mar 221,115179146Mar 231,376258170Mar 241,670339178Mar 251,875321342Mar 26
Peak revenue ₹1,875 Cr, year to Mar 2026; lowest ₹455 Cr, year to Mar 2017

Operating and net margin, per cent

  • Operating margin
  • Net margin
27.3%10.7%20.1%23.1%21.2%23.9%27.3%23.1%23.8%26.0%27.1%23.6%11.5%13.5%10.7%14.0%17.3%15.9%16.1%18.8%20.3%17.1%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 0.5% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue1,875
  2. Materials and goods−597
  3. Employee costs−402
  4. Other expenses−434
  5. Operating profit442
  6. Depreciation−116
  7. Other income+120
  8. One-off items−6.8
  9. Finance costs−18
  10. Profit before tax422
  11. Tax−107
  12. Joint ventures+5.7
  13. Net profit321

What the company owns

  • Plant, investments and other assets₹2,127 Cr
  • Current investments₹739 Cr
  • Receivables₹531 Cr
  • Inventory₹434 Cr
  • Cash and bank₹88 Cr

What pays for it: net worth and liabilities

  • Net worth₹3,149 Cr
  • Borrowings₹342 Cr
  • Other liabilities₹305 Cr
  • Owed to suppliers₹123 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Poly Medicure quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 25 MayJun 2026Twelve monthsFiled 7 Aug
Revenue from operations4555226116877869231,1151,3761,6701,8751,997
3644014815235727108501,0181,2171,4331,536
Materials and goods bought153165209217262348406483555597609
Employee costs87–117139142164203246302402457
Other expenses123–156167168198241289361434470
Operating profit before depreciation92120129164214213265358453442461
Operating margin20.1%23.1%21.2%23.9%27.3%23.1%23.8%26.0%27.1%23.6%23.1%
Materials, % of revenue33.7%–34.2%31.6%33.3%37.7%36.4%35.1%33.2%31.8%30.5%
Employee costs, % of revenue19.2%–19.1%20.2%18.0%17.7%18.2%17.9%18.1%21.5%22.9%
Other expenses, % of revenue27.0%–25.6%24.4%21.4%21.5%21.6%21.0%21.6%23.1%23.5%
Depreciation and amortisation242937414854576483116128
Operating profit after depreciation689192123167159208294370327333
Other income111418181838365989120111
Finance costs710121894911121822
Profit before one-off items and tax729699124177193236342447429423
One-off items011000000−7−7
Profit before tax7297100124177193236342447422416
2026353044495886114107109
Share of profit of joint ventures and associates1––23223566
52716596136147179258339321313
Other comprehensive income––00000−1−14647
Total comprehensive income––6596136147180257337367360
Net margin11.5%13.5%10.7%14.0%17.3%15.9%16.1%18.8%20.3%17.1%15.7%
Net margin without joint ventures and associates11.4%––13.6%16.9%15.6%15.9%18.6%20.0%16.8%–
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2018 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 25 May
3814359661,0871,2421,4702,7663,149
3814359661,0871,2421,4702,7663,106
Share capital4444484848485151
Reserves3373919181,0401,1941,4222,7153,055
Belonging to outside owners of subsidiaries0––––––43
137168102125146170178342
154197171227293351370576
1191358763423757194
Total assets6547671,2241,3771,5771,8593,1923,919
3524505185937701,0171,2751,977
3023187067838078421,9171,942
Net debt82126−272−227−155−116−1,030−485
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 25 May
119123191266241241
163171249340330342
−61−63−50−41−154−149
Receivables−34−51−29−37−85−99
Inventories−14−42−40−12−57−37
Payables02544−1012
Other working capital−135155−2−25
Tax paid−45−47−58−74−89−102
Capital spending95156239277325308
Free cash flow24−32−48−11−84−68
−436−85−179−241−1,191−225
317−35−13−2095320
Dividends paid02424293035
Shares bought back000000
Shares issued4000001,0000
Net change in cash03−15335
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Poly Medicure dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 25 May
Earnings per share₹5.93₹8.00₹7.41₹10.86₹15.25₹15.28₹18.69₹26.92₹34.13₹31.79
Diluted earnings per share₹5.93₹7.99₹7.41₹10.86₹15.24₹15.27₹18.67₹26.90₹34.11₹31.75
₹1.50₹2.00₹2.00₹2.00₹2.50₹2.50₹3.00₹3.00₹3.50₹3.50
As declared that year–₹2.00₹2.00₹2.00₹2.50₹2.50₹3.00₹3.00₹3.50₹3.50
Book value per share––₹43.22₹49.27₹100.71₹113.40₹129.41₹153.18₹272.95₹306.45
Dividend payout25.3%25.0%27.0%18.4%17.6%16.4%16.1%11.1%10.5%11.0%
Shareholder yield––––−5.5%0.3%0.3%0.2%−4.3%0.3%
Market cap at the year end (₹ crore)2,3962,2151,9372,0577,2579,1069,13815,24722,75012,073
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from. The dividend as declared is blank for the year to Mar 2017: its payments were declared on different share counts, a split or bonus between them, so they do not add to one figure.

Ratios

Consolidated, years to March.Poly Medicure PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 25 May
Revenue growth10.4%14.6%17.1%12.5%14.4%17.4%20.8%23.4%21.4%12.3%
Operating profit growth6.7%31.5%7.6%26.7%30.7%−0.6%24.5%35.0%26.4%−2.3%
Net profit growth8.4%34.9%−7.4%46.6%41.7%7.8%22.4%44.1%31.1%−5.3%
Earnings per share growth–34.9%−7.4%46.6%40.4%0.2%22.3%44.0%26.8%−6.9%
––17.1%23.5%19.4%14.3%15.4%19.0%16.0%11.0%
–––6.3 pts−4.1 pts−5.1 pts1.1 pts3.7 pts−3.1 pts−5.0 pts
From the net margin–––5.2 pts5.6 pts−1.6 pts0.2 pts2.6 pts1.5 pts−2.4 pts
From asset turnover–––0.8 pts−5.3 pts−1.8 pts0.9 pts1.1 pts−3.6 pts−2.7 pts
From borrowing–––0.4 pts−4.4 pts−1.7 pts0.0 pts0.0 pts−1.0 pts0.2 pts
Return on capital employed––17.8%20.5%15.6%13.1%15.0%17.9%12.6%9.4%
Cash conversion––––87.4%84.3%106.4%103.0%71.2%75.0%
Interest cover9.49.17.86.719.637.423.626.030.917.9
Debt to equity––0.360.390.110.120.120.120.060.11
Receivable days––77687382777276103
Inventory days––147189176177188167188265
Payable days––97112909383725775
Cash conversion cycle, days––126144159165182166207294
Working capital days––83729211511299113161
Asset turnover––0.930.970.790.710.760.800.660.53
Assets per rupee of net worth––1.711.741.421.271.271.271.191.21
Sales per rupee of plant––2.342.202.102.101.901.681.611.49
Capital spending to depreciation––––2.002.884.194.333.932.67
Plant being built, % of plant in use––3.6%5.3%3.9%8.5%12.4%8.1%8.6%7.2%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
9.1%
Cash from operations against operating profit
54.4%
Measure10 years5 years3 years
Revenue growth, yearly rate16.4%19.0%18.9%
Profit growth, yearly rate20.9%18.8%21.6%
Return on equity, average–15.1%15.3%
Return on capital employed, average–13.6%13.3%
Operating margin, average23.9%24.7%25.6%
Net margin, average15.5%17.6%18.7%
Asset turnover, average–0.690.66
Cash conversion cycle, days, average–203223
Interest cover, average18.827.124.9
Debt to equity, average–0.100.10

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations1,062748241
Cash from investing−1,922−1,657−225
Cash from financing90595320
Capital spending1,305910308
Dividends paid1429535
Shares bought back000
Shares issued for cash1,0011,0000
Borrowings raised858575
Borrowings repaid48210

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––537773
Altman Z-scorePublished threshold 1.81––6.766.1221.0421.5719.0126.3034.7511.77
Beneish M-scorePublished threshold −1.78––––−2.15−2.16−2.39−2.42−2.09−1.50
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––45.488.3311.3413.5751.028.59
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.940.990.900.82
Receivables growth less revenue growthOur threshold 0 percentage points–––−13.508.6714.67−6.88−8.718.1939.58
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––29.76−7.810.197.32−12.9714.2644.33
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––0.401.360.890.440.220.564.03
Assets under construction, years of additionsOur threshold 2 years of additions–––0.180.140.310.350.230.300.27
Effective tax ratePublished threshold 17.16 per cent27.8627.0434.6524.1525.0025.2824.7125.1725.4725.31
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––0.670.153.435.581.18
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
24 Jun 2026CRISIL Ratings LimitedBank FacilitiesCrisil AA-Review, OtherPositive264
24 Jun 2026CRISIL Ratings LimitedBank FacilitiesCrisil A1+Review, Re-affirm185.50
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.